Pharmaceuticals 2010, 3(8), 2674-2688; doi:10.3390/ph3082674

Overview of Histone Deacetylase Inhibitors in Haematological Malignancies

1 Cancer Immunology Research, Peter MacCallum Cancer Centre, Melbourne, Australia 2 Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Australia 3 University of Melbourne, Parkville, Melbourne, Australia
* Author to whom correspondence should be addressed.
Received: 23 July 2010; in revised form: 12 August 2010 / Accepted: 13 August 2010 / Published: 17 August 2010
(This article belongs to the Special Issue HDAC Inhibitors)
PDF Full-text Download PDF Full-Text [163 KB, uploaded 17 August 2010 08:43 CEST]
Abstract: Histone deacetylase inhibitors (HDACi) can induce hyperacetylation of both histone and non-histone target resulting in epigenetic reprogramming and altered activity, stability and localisation of non-histone proteins to ultimately mediate diverse biological effects on cancer cells and their microenvironment. Clinical trials have demonstrated single agent HDACi to have activity in hematological malignancies, in particular T-cell lymphoma and Hodgkin lymphoma. Combination strategies with standard therapies based on pre-clinical data are being employed with significant success due to their excellent side effect profile. Correlative studies will provide valuable information on the sub-groups of patients more likely to respond or be resistant to HDACi therapy, while long-term monitoring for toxicities is also needed.
Keywords: Histone deacetylase inhibitors; Clinical studies; Haematology

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Bishton, M.J.; Johnstone, R.W.; Dickinson, M.; Harrison, S.; Prince, H.M. Overview of Histone Deacetylase Inhibitors in Haematological Malignancies. Pharmaceuticals 2010, 3, 2674-2688.

AMA Style

Bishton MJ, Johnstone RW, Dickinson M, Harrison S, Prince HM. Overview of Histone Deacetylase Inhibitors in Haematological Malignancies. Pharmaceuticals. 2010; 3(8):2674-2688.

Chicago/Turabian Style

Bishton, Mark J.; Johnstone, Ricky W.; Dickinson, Michael; Harrison, Simon; Prince, H. Miles. 2010. "Overview of Histone Deacetylase Inhibitors in Haematological Malignancies." Pharmaceuticals 3, no. 8: 2674-2688.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert